Background: A Persistent Stability Challenge

The company developed an antihypertensive tablet with a two-year target shelf life. However, accelerated stability testing at 40°C/75% RH revealed unacceptable impurity growth beyond ICH limits after 3 months. The root cause was initially unclear, delaying submission timelines and risking market entry.

Initial Results:

• ⛔ Impurities exceeded 1.5% at accelerated conditions
• ⛔ Dissolution dropped from 90% to 70% in 6 months
• ⛔ Color change observed in some batches

Applying QbD to Uncover Root Causes

To address these challenges, the development team initiated a QbD framework as outlined in ICH Q8. They began by clearly defining the Quality Target Product Profile (QTPP), followed by risk assessment and Design of Experiments (DoE).

QTPP Highlights:

• ✅ Route: Oral
• ✅ Dose: 50 mg, once daily
• ✅ Intended shelf life: 24 months
• ✅ Storage: Room temperature (25°C/60% RH)

Risk Assessment (FMEA):

• ✅ API hygroscopicity = High risk
• ✅ Excipients (microcrystalline cellulose) = Medium risk
• ✅ Primary packaging (PVC blister) = High risk

Design of Experiments (DoE) to Identify Interactions

Using a 2³ full factorial DoE, the team evaluated the impact of three variables:

• ✅ Packaging type (PVC vs. Alu-Alu)
• ✅ Antioxidant concentration (0.0%, 0.2%, 0.5%)
• ✅ Granulation method (dry vs. wet)

Results showed a strong interaction between PVC and lack of antioxidant, leading to degradation under stress. Alu-Alu with 0.2% antioxidant mitigated impurity formation significantly.

Formulation & Process Improvements

Based on the DoE and risk analysis, the following modifications were made:

• ✅ Switched from PVC to Alu-Alu blister packaging
• ✅ Introduced 0.2% BHT (Butylated Hydroxytoluene) as antioxidant
• ✅ Optimized moisture content to <2% using dry granulation

These changes were implemented in pilot-scale batches and subjected to ICH stability testing.

Stability Results After QbD Optimization

The new formulation and packaging combination underwent both accelerated and real-time stability testing. The results were significantly improved:

• ✅ Impurities remained below 0.5% at 6 months (40°C/75%)
• ✅ Dissolution remained >85% for entire duration
• ✅ No visible color change observed

These data supported a 24-month shelf life assignment under ICH Zone IVb conditions.

Internal and Regulatory Alignment

The team documented the entire QbD journey in their regulatory submission:

• ✅ CTD Module 3.2.P.2 – Formulation development and risk assessment
• ✅ Module 3.2.P.5 – Control strategy linked to CQAs
• ✅ Module 3.2.P.8 – Justification of packaging and antioxidant inclusion

Additional guidance was taken from ICH guidelines to ensure global regulatory acceptability.

Broader Business Impact of the QbD Stability Approach

Implementing QbD principles not only solved the immediate stability issue but also created lasting improvements across the development organization:

• ✅ Reduced development cycle time by 5 months for future analog products
• ✅ Created a reusable risk template for FMEA in future projects
• ✅ Aligned global sites with a standardized QbD-based stability protocol

This streamlined approach increased confidence among cross-functional teams, including regulatory, analytical, and formulation development groups.

Lessons Learned from the QbD Stability Case

The case highlighted key takeaways relevant to any pharmaceutical company aiming to reduce risk and improve predictability in their stability programs:

• ✅ Packaging can be as critical as formulation in ensuring stability
• ✅ Excipients contribute significantly to degradation pathways
• ✅ DOE helps discover non-obvious interactions between variables
• ✅ QbD documentation helps streamline post-approval changes and variation filings

These lessons led to the creation of an internal “QbD playbook” for development teams.

Linking QbD to Regulatory Success

Regulatory reviewers from USFDA commended the clarity of justification for packaging selection and impurity control. The absence of major queries during review was attributed to the clear design space and robust control strategy based on CQAs and risk management.

Furthermore, post-approval changes to excipient suppliers and granulation process were handled via minor variation filings, supported by the original DOE and risk assessments. This reduced regulatory burden and time-to-implementation.

Technical Innovations That Emerged

This project also catalyzed technical upgrades:

• ✅ Adoption of real-time moisture analyzers in granulation suites
• ✅ Use of in-line NIR to monitor blend uniformity
• ✅ Custom-built stability chambers with tighter RH controls (±1.5%)

These systems now support other product lines, increasing overall product quality assurance.

Cost-Benefit Summary

Although packaging cost increased, the gain in shelf life and regulatory speed more than compensated for the expense.

Final Thoughts: From Case to Company-Wide QbD Culture

This QbD-based stability case is not just a success story — it’s a blueprint for organizational change. By treating stability as a science-driven, risk-managed process tied to product design, the company improved compliance, quality, and commercial outcomes. The learnings are now embedded in every new product development process.

QbD is not a regulatory buzzword — it is a powerful enabler of long-term pharmaceutical quality and risk reduction. If used effectively, as seen in this case, it can transform stability programs into strategic assets.